<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33431266</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0035-3787</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>177</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Revue neurologique</Title>
          <ISOAbbreviation>Rev Neurol (Paris)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Seizure incidence among neuromyelitis optica spectrum disorder patients.</ArticleTitle>
        <Pagination>
          <StartPage>655</StartPage>
          <EndPage>659</EndPage>
          <MedlinePgn>655-659</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2020.08.011</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0035-3787(20)30736-0</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuromyelitis optica spectrum disorders (NMOSDs) are a group of neuroinflammatory diseases, which mainly affect the optic nerve and spinal cord. NMOSD is an astrocytic channelopathy involving the aquaporin-4 (AQP4) water channels in the central nervous system. Patients can present with seizure attacks as a first manifestation or relapse. However, compared with multiple sclerosis (MS) or myelin oligodendrocyte glycoprotein encephalomyelitis (MOG-EM), seizure attacks are less frequent in NMOSD.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this study, we aimed to find out the incidence of seizure attacks during the disease course of 137 NMOSD patients who were registered in our centre from January 2011 till January 2020. Furthermore, we reviewed the literature for NMOSD cases with seizure attacks during their follow-up, in order to investigate the reason for this low incidence of seizures.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Only one of our patients (0.72%) experienced an episode of generalised tonic-clonic seizure during his follow-up.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Reviewing the literature revealed that although seizures are rare in NMOSD, AQP4 disruption possibly increases the risk of seizure attacks. We therefore concluded that the role of AQP4 in seizures is controversial and needs more investigation.</AbstractText>
          <CopyrightInformation>Copyright Â© 2020 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Etemadifar</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sabeti</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: sabetifateme@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khorvash</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mirbagheri</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nouri</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salari</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Rev Neurol (Paris)</MedlineTA>
        <NlmUniqueID>2984779R</NlmUniqueID>
        <ISSNLinking>0035-3787</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D063308">Myelin-Oligodendrocyte Glycoprotein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063308" MajorTopicYN="N">Myelin-Oligodendrocyte Glycoprotein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012640" MajorTopicYN="Y">Seizures</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Aquaporin 4</Keyword>
        <Keyword MajorTopicYN="N">Astrocyte</Keyword>
        <Keyword MajorTopicYN="N">Neuromyelitis optica</Keyword>
        <Keyword MajorTopicYN="N">Seizure</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>48</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33431266</ArticleId>
        <ArticleId IdType="doi">10.1016/j.neurol.2020.08.011</ArticleId>
        <ArticleId IdType="pii">S0035-3787(20)30736-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
